Please use this identifier to cite or link to this item: http://tcc.fps.edu.br:80/jspui/handle/fpsrepo/305
Title: Comprometimento perinatal na aloimunização eritrocitária RhD: série de casos
Authors: ALBUQUERQUE, Maria Eduarda Pires de Azevedo
VASCONCELOS, Maria Kamila Menezes Camilo
SOUZA, Alex Sandro Rolland
SCHETTINI, Juliana
Keywords: Anemia
Ultrassonografia com Doppler
Transfusão sanguínea intrauterina
Terapia fetal
Issue Date: 2016
Abstract: Objective: To describe the perinatal outcomes of women with eryhtrocytic alloimmunization. Method: a cross-sectional study analyzing secondary data from a database that followed about 83 RhD negative pregnant women at IMIP hospital during the period of 2011 to 2015. Were included 16 isoimmunized pregnant women who had positive irregular antibodies. We excluded 5 isoimmunized pregnant women who did not have their discharge summaries or neonatal information or couldn't be contacted for neonatal data to be collected. Results: The median maternal age was 33 years, 8 (72%) had less than 3 children, 6 (54.5%) had a history of newborn affected by hemolytic disease. We have obtained 11 fetuses with erythrocytic alloimmunization for the study. There were no cases of stillbirth, but there was 01 (9.1%) early neonatal death (<7 days), 03 (27.3%) fetuses underwent intrauterine transfusion, 05 (45.4%) infants underwent exsanguino-transfusion, 10 (90.1%) underwent phototherapy, 04 (36.4%) required oxygen therapy, 07 (63.6%) of ICU stay and 03 (27.3%) stayed in the NICU. The primary antibody was antierythrocytic anti-D and it was the main related to severe cases. Conclusion: maternal erythrocytic alloimunization is still a reality in our midst even with the advent of immunoprophylaxis. The anti-D antibody persists on being associated with more severe cases of perinatal compromise.
URI: http://tcc.fps.local:80/handle/fpsrepo/305
Appears in Collections:Medicina

Files in This Item:
File Description SizeFormat 
Artigo TCC.pdf732.64 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.